2026 Alzheimer’s Disease and Brain Health Briefing

Executive Summary

Alzheimer’s disease is a progressive, ultimately fatal neurodegenerative disorder characterized by specific brain changes that begin 20 years or more before the onset of clinical symptoms. As of 2026, an estimated 7.4 million Americans age 65 and older are living with clinical Alzheimer’s dementia, a figure projected to grow significantly as the population ages. The medical field is currently undergoing a paradigm shift, moving from a symptom-based diagnosis to a biological staging model facilitated by advances in biomarkers, including the first FDA-cleared blood tests.

While there is no cure, the treatment landscape now includes disease-modifying therapies—specifically lecanemab and donanemab—that target underlying biology to slow progression. Furthermore, research such as the U.S. POINTER study has substantiated that addressing modifiable risk factors through lifestyle interventions can protect cognitive function. Despite these advances, significant challenges remain, including profound underdiagnosis (particularly in early stages and among Black and Hispanic populations), the health and economic burden on unpaid caregivers, and the necessity for a more diverse and dementia-capable workforce.

--------------------------------------------------------------------------------

The Alzheimer’s Disease Continuum and Clinical Staging

The understanding of Alzheimer’s has evolved from a binary diagnosis to a continuum of progression. This spectrum ranges from unnoticeable brain changes to severe impairment of daily functions.

Revised Diagnostic Criteria (2024)

New criteria incorporate biomarkers to provide objective data for diagnosis and staging, moving away from purely clinical observations.

Stage

Clinical Description

Functional Impact

Stage 0

Asymptomatic; presence of deterministic genes (e.g., Down syndrome).

No evidence of clinical change.

Stage 1

Asymptomatic; biomarker evidence only (amyloid/tau).

Normal cognitive performance.

Stage 2

Transitional decline; subtle changes in mood or cognition.

Fully independent; minimal impact on daily life.

Stage 3

Cognitive impairment (similar to MCI).

Noticeable problems; difficulty with complex tasks (IADLs).

Stage 4

Mild functional impairment (Mild Dementia).

Independence in basic ADLs; needs help with complex tasks.

Stage 5

Moderate functional impairment.

Requires assistance with basic ADLs (bathing, dressing).

Stage 6

Severe functional impairment.

Complete dependence; loss of speech and mobility.

Distinction Between Dementia and Alzheimer’s

Dementia is a syndrome—a group of symptoms including loss of memory and problem-solving abilities—severe enough to interfere with daily life. Alzheimer’s disease is the most common cause of dementia, accounting for 60% to 80% of cases. However, "mixed dementia"—where Alzheimer’s brain changes coexist with other pathologies like vascular disease or Lewy bodies—is increasingly recognized as the norm, especially in individuals age 85 and older.

--------------------------------------------------------------------------------

Pathophysiology and Biomarkers

The hallmarks of Alzheimer’s are the accumulation of beta-amyloid plaques outside neurons and tau tangles inside neurons, leading to neuronal death and brain atrophy.

The 20-Year Lead Time

Research indicates that brain changes begin decades before memory loss:

• Beta-amyloid: Levels increase significantly up to 22 years before symptom onset.
• Glucose Metabolism: Decreases begin approximately 14 years before symptoms.
• Brain Atrophy: Structural changes are detectable up to 13 years before symptoms.

Advances in Detection

Biomarkers—measurable biological indicators—are now used to identify the disease earlier.

• Blood Tests: In 2025, the FDA cleared the first blood tests for Alzheimer’s. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is used for early detection in symptomatic individuals, while the Elecsys® pTau181 test is utilized in primary care to rule out Alzheimer's-related changes.
• Imaging and CSF: PET scans and cerebrospinal fluid (CSF) analysis remain critical for confirming the presence of amyloid and tau.

--------------------------------------------------------------------------------

Prevalence and Demographic Impact

The burden of Alzheimer’s is not distributed evenly across the U.S. population, influenced by age, sex, and race.

National and Regional Statistics

• Total Prevalence: 7.4 million Americans age 65+ (approximately 1 in 9).
• Age as a Driver: Prevalence rises from 5.2% in those age 65–74 to 35.8% in those 85 and older.
• Geography: The highest prevalence rates are found in the East and Southeast U.S. (e.g., Miami-Dade County at 16.6%, Baltimore City at 16.6%).

Disparities in Risk

• Sex: Nearly two-thirds of Americans with Alzheimer’s are women. This is partly due to longer life expectancy, though researchers are investigating "survival bias" and biological/societal differences.
• Race and Ethnicity: Black Americans are approximately twice as likely, and Hispanic Americans one and one-half times as likely, to have Alzheimer’s or other dementias compared to White Americans. These differences are largely attributed to social determinants of health (SDOH), such as inequities in education, socioeconomic status, and higher rates of cardiovascular risk factors.
• LGBTQIA+ Groups: Preliminary evidence suggests sexual and gender minority (SGM) older adults may face increased risk due to discrimination-related stressors and disparities in health care access.

--------------------------------------------------------------------------------

Treatment and Intervention

Modern management of Alzheimer’s involves a combination of pharmaceutical and lifestyle approaches.

Pharmaceutical Treatments

1. Disease-Modifying Therapies: Lecanemab (Leqembi®) and donanemab (Kisunla®) are monoclonal antibodies that remove beta-amyloid from the brain. They are indicated for individuals in early stages (Stages 3 and 4).
   • Benefits: They slow cognitive and functional decline. Lecanemab may extend independence by 10 months and donanemab by 13 months.
   • Side Effects: These include Amyloid-Related Imaging Abnormalities (ARIA), which can involve brain swelling or microhemorrhages. Regular MRI monitoring is required.
2. Symptomatic Treatments: Drugs like donepezil, rivastigmine, and memantine address cognitive symptoms by altering neurotransmitter levels but do not stop the underlying disease.
3. Neuropsychiatric Treatments: Brexpiprazole is FDA-approved for agitation associated with Alzheimer’s dementia.

Lifestyle and Non-Drug Interventions

The U.S. POINTER Study (2025) demonstrated that a structured lifestyle program significantly improves cognitive function in at-risk individuals. The "Brain Health Recipe" includes:

• Physical Exercise: 30–35 minutes of aerobic activity 4x/week plus strength training.
• Nutrition: Adherence to the MIND diet (leafy greens, berries, olive oil; limited sugar/fats).
• Cognitive/Social Activity: Brain training 3x/week and regular social engagement.
• Health Monitoring: Rigorous tracking of blood pressure and cholesterol.

--------------------------------------------------------------------------------

Societal and Systemic Challenges

The Underdiagnosis Crisis

A substantial portion of individuals meeting clinical criteria for dementia are not diagnosed.

• Only about half of Medicare beneficiaries with a diagnosis report being told of it.
• Underdiagnosis is highest at the earliest stages; only 8% of older Americans with Mild Cognitive Impairment (MCI) receive a diagnosis.
• Delayed diagnosis leads to missed opportunities for treatment and higher long-term costs.

Social Determinants of Health (SDOH)

The risk of dementia is profoundly impacted by the conditions in which people live and work. Lower socioeconomic status is associated with higher rates of diabetes, hypertension, and limited access to brain-healthy foods—all factors that compound dementia risk. Environmental factors, such as long-term exposure to fine particulate matter (PM2.5) air pollution, have also been linked to increased incident dementia.

Caregiving and Workforce

• Unpaid Care: Millions of family members provide billions of hours of unpaid care, often at a significant cost to their own physical, mental, and financial health.
• Workforce Shortage: There is a critical need for a "dementia-capable" workforce. Current shortages may result in long wait times for diagnostic testing as the demand for early-stage biological diagnosis increases.

--------------------------------------------------------------------------------

Important Quotes

• "Alzheimer’s begins 20 years or more before memory loss and other symptoms develop."
• "Mixed dementia is the norm, not just for those diagnosed with Alzheimer’s dementia based on symptoms, but also for those diagnosed with other types of dementia."
• "The U.S. POINTER study substantiated the power of lifestyle changes to impact brain health."
• "In the preclinical AD stage, Β amyloid can be detected... as much as 30 years before dementia occurs."